Magnesium for seizure prophylaxis in patients with mild preeclampsia

Obstetrics and Gynecology

Volumn 110, Issue 3, 2007, Pages 601-607

  Cahill, Alison G ^a   Macones, George A ^a   Odibo, Anthony O ^a   Stamilio, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; ANTIHYPERTENSIVE AGENT;

ARTICLE; BLOOD PRESSURE MONITORING; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DECISION MAKING; DISEASE SEVERITY; FEMALE; HEART ARREST; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MATERNAL MORTALITY; MONTE CARLO METHOD; NEWBORN MORTALITY; OUTCOME ASSESSMENT; PREECLAMPSIA; PRIORITY JOURNAL; PROBABILITY; PROTEINURIA; SEIZURE; SENSITIVITY ANALYSIS; SIMULATION; SOLUTIO PLACENTAE; TREATMENT OUTCOME; ANTIHYPERTENSIVE THERAPY; MAGNESIUM TOXICITY; MAINTENANCE DRUG DOSE; PROPHYLAXIS; RISK BENEFIT ANALYSIS; TOXICITY;

ADULT; ANTICONVULSANTS; FEMALE; HUMANS; INFANT MORTALITY; INFANT, NEWBORN; MAGNESIUM; MAGNESIUM SULFATE; MATERNAL MORTALITY; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PROBABILITY; RISK ASSESSMENT; SEIZURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34548427778     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000279152.66491.78     Document Type: Article

References (22)

1. ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002;99:159-67.
2. Miniño AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep 2006;54:1-49.
3. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomized placebo-controlled trial. Lancet 2002;359:1877-90.
4. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995;333:201-5.
5. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1997;176:623-7.
6. Livingston JC, Livingston LW, Ramsey R, Mabie BC, Sibai BM. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003;101:217-20.
7. Naglie G, Krahn MD, Naimark D, Redelmeier DA, Detsky AS. Primer on medical decision analysis: Part 3-estimating probabilities and utilities. Med Decis Making 1997;17:136-41.
8. Coetzee EJ, Dommisse J, Anthony J. Randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998;105:300-3.
9. Belfort MA, Anthony J, Saade GR, Allen JC Jr, Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003;348:304-11.
10. Magee LA, Miremadi S, Li J, Cheng C, Ensom MH, Carleton B, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005;193:153-63.
11. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990;163:1049-54.
12. Perinatal Mortality Data File, 2001 (CD-ROM), PB2004-500166. Springfield (VA): U.S. Dept. of Commerce, Technology Administration, National Technical Information Service;2004.
13. Vandenbussche FP, De Jong-Potjer LC, Stiggelbout AM, Le Cessie S, Keirse MJ. Differences in the valuation of birth outcomes among pregnant women, mothers, and obstetricians. Birth 1999;26:178-83.
14. Pham CT, Crowther CA. Birth outcomes: utility values that postnatal women, midwives and medical staff express. BJOG 2003;110:121-7.
15. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637.
16. Ananth CV, Wilcox AJ. Placental abruption and perinatal mortality in the United States. Am J Epidemiol 2001;153:332-7.
17. Department of Health and Human Services, Centers for Disease Control and Prevention. Provisional 2003 documentation: mortality multiple cause-of-death public use record, 2003. Available at: http://www.cdc.gov/nchs/data/dvs/ Record_Layout_2003.pdf. Retrieved July 3, 2007. p. 49-50.
18. Heinonen S, Saarikoski S. Reproductive risk factors of fetal asphyxia at delivery: a population based analysis. J Clin Epidemiol 2001;54:407-10.
19. Brozek JL, Guyatt GH, Schunemann HJ. How a well-grounded minimal important difference can enhance transparency of labeling claims and improve interpretation of a patient reported outcome measure. Health Qual Life Outcomes 2006;4:69.
20. Kulkarni AV. Distribution-based and anchor-based approaches provided different interpretability estimates for the Hydrocephalus Outcome Questionnaire. J Clin Epidemiol 2006;59:176-184.
21. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523-32.
22. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: evidence from randomized trials. Clin Obstet Gynecol 2005;48:478-88.